Código QR (código de barras bidimensional)

PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer

PurposeTriple-negative breast cancer (TNBC) is a highly challenging subtype due to a unique tumor microenvironment. Several evidence (IMpassion130 trial and KEYNOTE-355 trial) supported the therapeutic effect of the immune checkpoint inhibitor in TNBC. However, the efficacy and safety of the PD-1 in...

ver descrição completa

Na minha lista:
Principais autores: Yan Jia, Jie Zhang, Yehui Shi, Guolei Dong, Xiaojing Guo, Zhongsheng Tong
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-10-01
coleção:Frontiers in Cell and Developmental Biology
Assuntos:
immune checkpoint inhibitor
sintilimab
triple-negative breast cancer
immunotherapy
tumor microenvironment
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fcell.2024.1430310/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados